amylin vs glp 1 The current range of weight-loss drugs on the market targets GLP-1 receptors. Seeking a new generation of weight-loss drugs, some companies are developing analogs. Read more at the link in our The protective effect of amylin
Description
Gastric ultrasound identifies increased residual gastric contents in patients on GLP-1 receptor agonists, showing that shorter drug withholding and fasting times are linked to higher aspiration risk before anesthesia.
...And "Ozempic breath" could be the driver
Credits: istock.org
Learn what retatrutide does and how it affects appetite, blood sugar and energy use
they facilitate weight loss and the decrease of body fat
and is not a GLP-1 agonist drug.**
